表纸
市场调查报告书
商品编码
1151822

全球癌症/肿瘤分析市场:按技术(免疫测定,NGS,PCR),癌症类型(乳腺癌、肺癌、结直肠癌),生物标誌物类型(基因/蛋白质),生物标誌物发现,诊断,预后应用预测到2027

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027

出版日期: | 出版商: MarketsandMarkets | 英文 295 Pages | 订单完成后即时交付

价格
  • 全貌
  • 简介
  • 目录
简介

全球癌症/肿瘤分析市场规模预计将从 2022 年的 97 亿美元增长到 2027 年的 160 亿美元,预测期内復合年增长率为 10.6%。

主要的市场驱动力包括增加对癌症研究的资助和分析技术的进步。此外,个性化医疗的日益普及和对 PoC(即时护理)诊断的需求不断增长,预计在预测期内将为市场参与者提供重要的增长机会。另一方面,与样本采集和存储相关的技术挑战在一定程度上抑制了市场增长。

从技术来看,免疫分析部分将在 2021 年占据最大的市场份额。促成因素包括它在癌症诊断和预后中的应用,对确定适当治疗策略的支持,以及广泛用作测量标本中分析物的存在和浓度的金标准。

按癌症类型划分,预计肺癌部分在预测期内的复合年增长率最高。其原因包括对早期诊断的需求增加和肺癌的高发病率。

按生物标誌物类型划分,遗传生物标誌物部分在 2021 年占据了最大份额。这其中的因素包括高通量技术的进步以及在癌症诊断和预后领域的传播和渗透。

按应用划分,研究应用将在 2021 年占据最大份额,其次是临床应用。研究应用的很大一部分是由于个性化医疗领域的迅速扩大和癌症研究资金的增加。

到 2021 年,北美将占据最大份额,其次是欧洲、亚太地区、拉丁美洲以及中东和非洲。北美的高市场份额被认为是由于对生物标誌物发现和开发的投资增加、对个性化治疗药物的需求增加以及用于癌症研究的先进组学技术的传播。

本报告分析了全球癌症/肿瘤分析市场,包括市场的基本结构和最新发展、主要市场驱动和限制因素,按发动机、部件、车辆类型、支持技术,我们正在调查各地区市场趋势展望、市场竞争状况和主要公司概况。

内容

第一章介绍

第二章研究方法论

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 介绍
  • 市场动态
  • 行业趋势
    • 组学数据整合
    • 液体活检的进展
    • 用于个性化医疗的类器官
    • 增加研发 (R&D) 投资以开发新的活性物质

第 6 章癌症/肿瘤分析市场:按技术分类

  • 介绍
  • 免疫测定
  • NGS(下一代测序)
  • PCR(聚合□炼式反应)
  • 原位杂交
  • 微阵列
  • 质谱
  • 其他技术

第 7 章癌症/肿瘤分析市场:按癌症类型分类

  • 介绍
  • 乳腺癌
  • 肺癌
  • 结直肠癌
  • 前列腺癌
  • 黑色素瘤
  • 其他癌症

第 8 章癌症/肿瘤分析市场:按生物标誌物类型分类

  • 介绍
  • 遗传生物标誌物
  • 蛋白质生物标誌物
  • 其他生物标誌物

第 9 章癌症/肿瘤分析市场:按应用

  • 介绍
  • 研究用途
    • 生物标誌物发现
    • 个性化医疗
  • 临床应用
    • 诊断
    • 预后
    • 监测和治疗
    • 放映

第 10 章癌症/肿瘤分析市场:按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 其他亚太国家
  • 拉丁美洲
  • 中东和非洲

第11章竞争格局

  • 概览
  • 主要公司采用的策略
  • 主要公司的收入份额分析
  • 市场份额分析
  • 公司评估象限
  • 竞争场景
    • 产品发布和批准
    • 资本交易
    • 其他

第12章公司简介

  • 主要公司
    • ILLUMINA, INC.
    • QIAGEN N.V.
    • NEOGENOMICS, INC.
    • SYSMEX CORPORATION
    • HTG MOLECULAR DIAGNOSTICS, INC.
    • PREDICTIVE ONCOLOGY, INC.(HELOMICS CORPORATION)
    • CARIS LIFE SCIENCES
    • NANOSTRING TECHNOLOGIES, INC.
    • GUARDANT HEALTH, INC.
    • FOUNDATION MEDICINE, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • THERMO FISHER SCIENTIFIC INC.
    • GENSCRIPT BIOTECH CORPORATION
    • TEMPUS LABS
    • HOLOGIC, INC.
    • EXACT SCIENCES
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • PERSONALIS, INC.
  • 其他企业
    • BOREAL GENOMICS INC.
    • STRAND LIFE SCIENCES
    • LUCENCE HEALTH, INC.
    • ACT GENOMICS CO., LTD.
    • IMB DX, INC.
    • PERTHERA
    • AGENDIA

第13章 附录

目录
Product Code: MD 4803

The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period. Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing preference for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, technical issues with sample collection and storage are factors restraining the market growth to a certain extent.

Based on technology, the immunoassays segment accounted for the largest market share of the cancer/tumor profiling market

Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of in 2021. This large share can be attributed to the its use in the diagnosis and prognosis of cancer, they aid in making appropriate treatment decisions, and adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample.

Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period

Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. During the forecast period, the lung cancer segment is expected to register the highest CAGR. This can be attributed to the increasing need for early diagnosis and the high incidence rate of lung cancer.

Based on biomarker type, the genomic biomarker segment accounted for the largest share during the forecast period

Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers. In 2021, the genomic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the advancements in high-throughput technologies and high adoption of these biomarkers during cancer diagnosis and prognosis.

Based on applications, the research application segment holds the largest market share during the forecast period

Based on application, the cancer/tumor profiling market has been segmented into research and clinical applications. In 2021, research applications accounted for the largest share of the cancer/tumor profiling market, followed by clinical applications. The large share of the research segment can be attributed to the rapidly growing field of personalized medicine and increasing funding for cancer research.

North America is expected to account for the largest share of the cancer/tumor profiling market in 2021

In 2021, North America accounted for the largest share of the cancer/tumor profiling market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. The large share of this market segment can be attributed to the increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics and rising adoption of advanced omics technologies for cancer research.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-35%, Tier 2-45%, and Tier 3-20%
  • By Designation - C-level-35%, Director-level-25%, Others-40%
  • By Region - North America-45%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle East and Africa-5%

Key players in cancer/tumor profiling the market

The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), Sysmex Corporation (Japan), HTG Molecular Diagnostics, Inc. (US), Helomics Corporation (US), Caris Life Sciences (US), NanoString Technologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).

Research Coverage:

The report analyzes the cancer/tumor profiling and aims at estimating the market size and future growth potential of this market based on various segments such as technology, cancer type, biomarker type, application, and region. The report also includes a product portfolio matrix of various cancer/tumor profiling companies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by technology, cancer type, biomarker type, application, and region
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
  • Market Development: Comprehensive information on the lucrative emerging markets by technology, cancer type, biomarker type, application, and region
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 CANCER/TUMOR PROFILING MARKET
    • 1.2.3 YEARS CONSIDERED
  • 1.3 CURRENCY CONSIDERED
    • TABLE 1 AVERAGE ANNUAL EXCHANGE RATES USED IN THIS REPORT FOR CURRENCY CONVERSIONS TO USD ARE AS FOLLOWS:
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZING & VALIDATION APPROACH
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 CANCER/TUMOR PROFILING MARKET: SEGMENTAL SHARE ANALYSIS
    • FIGURE 7 TOP-DOWN APPROACH
    • FIGURE 8 CAGR PROJECTIONS
    • FIGURE 9 IMPACT ON MARKET GROWTH & CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: CANCER/TUMOR PROFILING MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

4 PREMIUM INSIGHTS

  • 4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
    • FIGURE 16 INCREASING INCIDENCE OF CANCER AND RISING PREFERENCE FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021)
    • FIGURE 17 GENETIC BIOMARKERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
  • 4.3 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 CANCER/TUMOR PROFILING MARKET: REGIONAL MIX (2022-2027)
    • FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027)
    • FIGURE 20 EMERGING ECONOMIES TO REGISTER A HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of cancer
    • FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
      • 5.2.1.2 Increasing use of biomarkers in cancer profiling
      • 5.2.1.3 Growing investments in cancer research
      • 5.2.1.4 Technological advancements in cancer profiling techniques
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments for biomarker discovery & development
    • TABLE 3 TIMEFRAME FOR BIOMARKER DEVELOPMENT
      • 5.2.2.2 Technical issues related to sample collection & storage
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing preference for personalized medicine
    • FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
      • 5.2.3.2 Rising need for point-of-care diagnostics
    • TABLE 4 POC DETECTION TOOLS FOR CANCER (BY CANCER & SAMPLE TYPE)
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Low biomarker discovery-to-approval ratio
    • FIGURE 24 KEY ISSUES AND CHALLENGES IN CLINICAL TRANSLATION OF BIOMARKERS
      • 5.2.4.2 Poor regulatory and reimbursement scenario
    • TABLE 5 CANCER/TUMOR PROFILING MARKET: DRIVES, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 INTEGRATION OF OMICS DATA
    • TABLE 6 CANCER-SPECIFIC MULTI-OMICS DATA RESOURCES
    • 5.3.2 ADVANCES IN LIQUID BIOPSY
    • 5.3.3 ORGANOIDS FOR PERSONALIZED MEDICINE
    • TABLE 7 CLINICAL TRIALS CONDUCTED FOR ASSESSING DRUG SENSITIVITY USING ORGANOID METHODS (2021)
    • 5.3.4 INCREASING R&D INVESTMENTS FOR DEVELOPING NOVEL ACTIVE SUBSTANCES

6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 8 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 9 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027(USD MILLION)
  • 6.2 IMMUNOASSAYS
    • 6.2.1 PROVISION OF IMPROVED THERAPEUTIC CHOICES FOR DISEASE ASSESSMENT & DIAGNOSIS TO DRIVE MARKET
    • TABLE 10 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 11 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.3 NEXT-GENERATION SEQUENCING
    • 6.3.1 RISING ADVANCEMENTS IN NGS TESTS TO DRIVE MARKET
    • TABLE 12 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 13 CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.4 POLYMERASE CHAIN REACTION
    • 6.4.1 REAL-TIME PCR USED FOR BIOMARKER VALIDATION TO DRIVE MARKET
    • TABLE 14 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 15 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.5 IN SITU HYBRIDIZATION
    • 6.5.1 FISH EVALUATION FOR KEY BIOMARKERS TO DRIVE MARKET
    • TABLE 16 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 17 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.6 MICROARRAYS
    • 6.6.1 PREDICTING RECURRENCE OF CANCER POST-TREATMENT TO DRIVE MARKET
    • TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 19 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.7 MASS SPECTROMETRY
    • 6.7.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR RAPID & RELIABLE DIAGNOSTICS TO DRIVE MARKET
    • TABLE 20 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 21 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2027 (USD MILLION)
  • 6.8 OTHER TECHNOLOGIES
    • TABLE 22 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 23 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2022-2027 (USD MILLION)

7 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE

  • 7.1 INTRODUCTION
    • TABLE 24 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 25 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
  • 7.2 BREAST CANCER
    • 7.2.1 RISING RESEARCH COLLABORATIONS ON BREAST CANCER DIAGNOSTICS TO DRIVE MARKET
    • TABLE 26 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 27 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 28 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.3 LUNG CANCER
    • 7.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS TO DRIVE MARKET
    • FIGURE 25 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
    • TABLE 29 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 30 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 31 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.4 COLORECTAL CANCER
    • 7.4.1 MOLECULAR PROFILING OF PRIMARY CRC TUMORS WITH ADJUVANT THERAPY TO DRIVE MARKET
    • FIGURE 26 COLORECTAL CANCER INCIDENCE RATE FOR KEY COUNTRIES (2018)
    • TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 33 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 34 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.5 PROSTATE CANCER
    • 7.5.1 DEVELOPMENT OF DIAGNOSTIC & PROGNOSTIC MOLECULAR BIOMARKER TESTS TO DRIVE MARKET
    • FIGURE 27 PROSTATE CANCER INCIDENCE RATE, BY REGION (2020)
    • TABLE 35 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 36 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.6 MELANOMA
    • 7.6.1 USAGE OF RT-QPCR FOR DETECTION OF MELANOMAS TO DRIVE MARKET
    • TABLE 37 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 38 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 39 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY, 2022-2027 (USD MILLION)
  • 7.7 OTHER CANCERS
    • FIGURE 28 LEUKEMIA MORTALITY RATE, BY REGION (2020)
    • TABLE 40 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2022-2027 (USD MILLION)

8 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE

  • 8.1 INTRODUCTION
    • TABLE 42 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 43 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
  • 8.2 GENETIC BIOMARKERS
    • 8.2.1 DECISION-MAKING CAPABILITIES FOR TARGETED THERAPIES
    • TABLE 44 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 45 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 8.3 PROTEIN BIOMARKERS
    • 8.3.1 HIGH SPECIFICITY FOR CANCER DETECTION & DIAGNOSIS
    • TABLE 46 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 47 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2022-2027 (USD MILLION)
  • 8.4 OTHER BIOMARKERS
    • TABLE 48 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 49 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2022-2027 (USD MILLION)

9 CANCER/TUMOR PROFILING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 50 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
    • TABLE 51 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2022-2027 (USD MILLION)
  • 9.2 RESEARCH APPLICATIONS
    • TABLE 52 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 53 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 54 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 55 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.2.1 BIOMARKER DISCOVERY
      • 9.2.1.1 Development of personalized medicine and drug development to support market
    • TABLE 56 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 57 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.2.2 PERSONALIZED MEDICINE
      • 9.2.2.1 Rising funding activities in precision medicine to support market
    • TABLE 58 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 59 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2027 (USD MILLION)
  • 9.3 CLINICAL APPLICATIONS
    • TABLE 60 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 61 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 62 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 63 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.1 DIAGNOSTICS
      • 9.3.1.1 Rising need for early-stage disease diagnosis and innovative product launches to drive market
    • TABLE 64 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 65 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.2 PROGNOSTICS
      • 9.3.2.1 Advancements in molecular biology to drive uptake of tumor profiling
    • TABLE 66 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 67 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.3 MONITORING & TREATMENT
      • 9.3.3.1 Multiplatform profiling analysis for cancer patients to drive market
    • TABLE 68 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 69 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY, 2022-2027 (USD MILLION)
    • 9.3.4 SCREENING
      • 9.3.4.1 Screening tests to help high-risk patients ascertain outcomes
    • TABLE 70 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 71 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY, 2022-2027 (USD MILLION)

10 CANCER/TUMOR PROFILING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 29 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2021)
    • TABLE 72 CANCER/TUMOR PROFILING MARKET, BY REGION, 2018-2021 (USD MILLION)
    • TABLE 73 CANCER/TUMOR PROFILING MARKET, BY REGION, 2022-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • TABLE 74 NORTH AMERICA: NEW CANCER CASES, BY CANCER TYPE (2020)
    • FIGURE 30 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 31 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 76 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022-2027 (USD MILLION)
    • TABLE 77 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 78 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 79 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 80 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 82 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 84 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 86 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 High R&D investments for cancer biomarker research to drive market
    • TABLE 87 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 88 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 89 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 90 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 91 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 92 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 93 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 94 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 95 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 96 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 97 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Rising government initiatives for discovery & development of cancer biomarkers to drive market
    • TABLE 98 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 99 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 100 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 101 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 102 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 103 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 104 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 105 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 106 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 107 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 108 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 32 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
    • TABLE 109 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 110 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022-2027 (USD MILLION)
    • TABLE 111 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 112 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 113 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 115 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 116 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 117 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 118 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 119 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Favorable government health policies to drive market
    • TABLE 121 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 122 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 123 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 124 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 125 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 126 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 127 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 128 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 129 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 130 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 131 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Availability of government funding and strategic collaborations with biotech firms to drive market
    • TABLE 132 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 133 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 134 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 135 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 136 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 137 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 138 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 139 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 140 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 141 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 142 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Growing government investments in genomics & proteomics research to drive market
    • TABLE 143 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 144 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 145 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 146 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 147 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 148 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 149 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 150 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 151 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 152 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 153 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Rising research activities for discovery of novel cancer biomarkers using tissue diagnostics to drive market
    • TABLE 154 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 155 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 156 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 157 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 158 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 159 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 160 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 161 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 162 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 163 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 164 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising incidence of cancer to drive demand for biomarkers
    • TABLE 165 SPAIN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 166 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 167 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 168 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 169 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 170 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 171 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 172 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 173 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 174 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 175 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.3.6 REST OF EUROPE (ROE)
    • TABLE 176 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 177 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 178 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 179 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 180 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 181 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 182 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 183 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 184 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 185 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 34 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 186 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2022-2027 (USD MILLION)
    • TABLE 188 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 189 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 190 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, Y TYPE, 2022-2027 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Increasing initiatives to boost genomic research to support market
    • TABLE 198 JAPAN: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
    • TABLE 199 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 200 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 201 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 202 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 203 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 204 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 205 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 206 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 207 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 208 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Rising government investments in genomics technologies to drive demand for tumor profiling products
    • TABLE 209 CHINA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
    • TABLE 210 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 211 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 212 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 213 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 214 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 215 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 216 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 217 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 218 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 219 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Rising demand for early cancer diagnosis due to increasing cancer burden to support market
    • TABLE 220 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 221 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 222 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 223 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 224 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 225 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 226 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 227 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 228 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 229 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 230 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC (ROAPAC)
    • TABLE 231 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 232 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 233 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 234 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 235 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 236 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 237 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 238 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 239 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 240 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 GROWING RESEARCH ACTIVITIES IN PRECISION ONCOLOGY TO SUPPORT MARKET
    • TABLE 241 LATIN AMERICA: CANCER INCIDENCE BY CANCER TYPE, 2020 VS. 2040
    • TABLE 242 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 243 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 244 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 245 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 246 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 247 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 249 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 250 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 251 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING ESTABLISHMENT OF PHARMA RESEARCH COMPANIES TO DRIVE DEMAND FOR CANCER DIAGNOSTICS
    • TABLE 252 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2018-2021 (USD MILLION)
    • TABLE 253 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2022-2027 (USD MILLION)
    • TABLE 254 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2018-2021 (USD MILLION)
    • TABLE 255 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2022-2027 (USD MILLION)
    • TABLE 256 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2018-2021 (USD MILLION)
    • TABLE 257 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2022-2027 (USD MILLION)
    • TABLE 258 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 259 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)
    • TABLE 260 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2018-2021 (USD MILLION)
    • TABLE 261 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 36 NEXT-GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER (2021)
    • FIGURE 37 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER (2021)
    • FIGURE 38 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER (2021)
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION QUADRANT (2021)
  • 11.6 COMPETITIVE SCENARIO
    • 11.6.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 262 PRODUCT LAUNCHES & APPROVALS (JANUARY 2019-OCTOBER 2022)
    • 11.6.2 DEALS
    • TABLE 263 DEALS (JANUARY 2019-OCTOBER 2022)
    • 11.6.3 OTHERS
    • TABLE 264 OTHERS (JANUARY 2019-OCTOBER 2022)

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ILLUMINA, INC.
    • TABLE 265 ILLUMINA, INC: BUSINESS OVERVIEW
    • FIGURE 40 ILLUMINA, INC: COMPANY SNAPSHOT (2021)
    • 12.1.2 QIAGEN N.V.
    • TABLE 266 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 41 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.3 NEOGENOMICS, INC.
    • TABLE 267 NEOGENOMICS, INC: BUSINESS OVERVIEW
    • FIGURE 42 NEOGENOMICS, INC: COMPANY SNAPSHOT (2021)
    • 12.1.4 SYSMEX CORPORATION
    • TABLE 268 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.5 HTG MOLECULAR DIAGNOSTICS, INC.
    • TABLE 269 HTG MOLECULAR DIAGNOSTICS, INC.: BUSINESS OVERVIEW
    • FIGURE 44 HTG MOLECULAR DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021)
    • 12.1.6 PREDICTIVE ONCOLOGY, INC. (HELOMICS CORPORATION)
    • TABLE 270 PREDICTIVE ONCOLOGY, INC.: BUSINESS OVERVIEW
    • FIGURE 45 PREDICTIVE ONCOLOGY, INC: COMPANY SNAPSHOT (2021)
    • 12.1.7 CARIS LIFE SCIENCES
    • TABLE 271 CLARIS LIFE SCIENCES: BUSINESS OVERVIEW
    • 12.1.8 NANOSTRING TECHNOLOGIES, INC.
    • TABLE 272 NANOSTRING TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 46 NANOSTRING TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021)
    • 12.1.9 GUARDANT HEALTH, INC.
    • TABLE 273 GUARDANT HEALTH, INC: BUSINESS OVERVIEW
    • FIGURE 47 GUARDANT HEALTH, INC: COMPANY SNAPSHOT (2021)
    • 12.1.10 FOUNDATION MEDICINE, INC.
    • TABLE 274 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
    • 12.1.11 F. HOFFMANN-LA ROCHE LTD
    • TABLE 275 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
    • FIGURE 48 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
    • 12.1.12 THERMO FISHER SCIENTIFIC INC.
    • TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 49 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2021)
    • 12.1.13 GENSCRIPT BIOTECH CORPORATION
    • TABLE 277 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
    • FIGURE 50 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.14 TEMPUS LABS
    • TABLE 278 TEMPUS LABS: BUSINESS OVERVIEW
    • 12.1.15 HOLOGIC, INC.
    • TABLE 279 HOLOGIC, INC: BUSINESS OVERVIEW
    • FIGURE 51 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
    • 12.1.16 EXACT SCIENCES
    • TABLE 280 EXACT SCIENCES: BUSINESS OVERVIEW
    • FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2021)
    • 12.1.17 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 281 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
    • FIGURE 53 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
    • 12.1.18 PERSONALIS, INC.
    • TABLE 282 PERSONALIS, INC: BUSINESS OVERVIEW
    • FIGURE 54 PERSONALIS, INC.: COMPANY SNAPSHOT (2021)
  • 12.2 OTHER PLAYERS
    • 12.2.1 BOREAL GENOMICS INC.
    • TABLE 283 BOREAL GENOMICS, INC: BUSINESS OVERVIEW
    • 12.2.2 STRAND LIFE SCIENCES
    • TABLE 284 STRAND LIFE SCIENCES: BUSINESS OVERVIEW
    • 12.2.3 LUCENCE HEALTH, INC.
    • TABLE 285 LUCENCE HEALTH, INC.: BUSINESS OVERVIEW
    • 12.2.4 ACT GENOMICS CO., LTD.
    • TABLE 286 ACT GENOMICS CO., LTD.: BUSINESS OVERVIEW
    • 12.2.5 IMB DX, INC.
    • TABLE 287 IMB DX, INC.: BUSINESS OVERVIEW
    • 12.2.6 PERTHERA
    • TABLE 288 PERTHERA: BUSINESS OVERVIEW
    • 12.2.7 AGENDIA
    • TABLE 289 AGENDIA: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 CUSTOMIZATION OPTIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS